Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Dupuytren's disease of the hand © SHUTTERSTOCK
Shutterstock

Researchers at the Kennedy Institute, University of Oxford, led by Professor Jagdeep Nanchahal have demonstrated the efficacy of the anti-TNF drug adalimumab for patients with early stage Dupuytren's disease.

"This phase 2b trial represents the clinical translation of our laboratory findings, where we identified TNF as a potential therapeutic target followed by a phase 2a dose ranging trial which showed that the highly concentrated formulation injected directly into the diseased tissues was effective in downregulating myofibroblasts, the cells responsible for fibrosis," said Jagdeep Nanchahal, Oxford Professor of Hand, Plastic and Reconstructive Surgery. "We also found the treatment to be completely safe and there were no related serious adverse events."

Dupuytren's disease is a common condition of the hand that affects about 5% of the UK population and tends to run in families. It causes the fingers to curl irreversibly into the palm and can be extremely disabling. There is currently no treatment for early disease and typically people have to wait until the condition deteriorates when surgery can be performed.

The trial recruited 140 participants with early-stage Dupuytren's disease who were randomised to receive 4 injections at 3 monthly intervals of either adalimumab (40mg adalimumab in 0.4ml) or saline. The primary outcome was nodule hardness measured at 12 months, and patients were followed up for a total of 18 months.

Published in The Lancet Rheumatology, the study found that the patients receiving adalimumab experienced softening and reduction in size of the treated nodule. Although adalimumab only has a half-life of about two or three weeks the researchers saw continued effects nine months after the last injection, indicating a sustained treatment effect.

"This could be a game-changer for patients who suffer from this disabling condition," said Professor Chris Buckley, Director of Clinical Research at the Kennedy Institute. "Dupuytren's disease is easy to spot at an early stage, so by starting a course of anti-TNF injections could bring long lasting respite and prevent the disease advancing to the stage that surgery is needed."

The research was funded by the Health Innovation Challenge Fund (Wellcome Trust, Department of Health and Social Care) and 180 Life Sciences.

Similar stories

New research suggests targeting blood vessels could be key to controlling fibrotic disease

By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.

Defining the role of resident memory B cells in the fight against influenza

Researchers at the Kennedy Institute of Rheumatology have used 3D and live-imaging to show how resident memory B cells boost antibodies to fight influenza.

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

The COVID-19 Multi-omic Blood Atlas (COMBAT) has identified blood hallmarks of COVID-19 involving particular immune cell populations and their development, components of innate and adaptive immunity, and connectivity with the inflammatory response.

Professor Chris Buckley joins the Kennedy Institute as Director of Clinical Research

Moving to the University of Oxford with the Arthritis Therapy Acceleration Programme (A-TAP) will help accelerate the discovery of new treatments for inflammatory diseases.

Behind enemy lines: research finds a new ally in the fight against cardiovascular disease hidden within the vessel wall itself

A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters "good" macrophage behaviour within the vessel wall.

New Oxford-Zeiss Centre of Excellence opens at the University of Oxford

The Kennedy Institute for Rheumatology and the Institute of Developmental and Regenerative Medicine announce the launch of the Oxford-Zeiss Centre of Excellence, providing state-of-the-art imaging technologies to lead future discoveries in global health and disease.